Drug Trial Radar · NCT05627856
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4
Actual
Start
Feb 21, 2023
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- Nov 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To explore the safety and efficacy of GNC-038 in relapsed or refractory NK/T cell lymphoma, vascular immunomother T cell lymphoma, and other relapsed or refractory NHL, and to determine MTD, MAD, DLT, and RP2D of GNC-038, as well as its pharmacokinetic characteristics and immunogenicity.
Conditions
- NK/T Cell Lymphoma
- Vascular Immunomother T Cell Lymphoma
- Non-Hodgkin Lymphoma
Interventions
GNC-038Drug
Administration by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Dose Limited Toxicity (DLT)Time frame: Up to 16 days after the first dose
- Phase Ib: Maximum Tolerated dose (MTD) or maximum administered dose (MAD)Time frame: Up to 16 days after the first dose
- Phase Ib: Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
- Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to 16 days after the first dose
- Phase II: Objective response rate (ORR)Time frame: Up to approximately 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.